Pasithea Therapeutics Activates Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Pasithea Therapeutics has activated two clinical trial sites in South Korea for its Phase 1/1b trial of PAS-004 in adult NF1 patients. The trial aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of PAS-004. The first patient in South Korea has been dosed, and the clinical sites are actively recruiting NF1 participants. The trial is expected to contribute to the development of meaningful treatment options for NF1 patients.